Navigation Links
Fast Forward, LLC and Provid Pharmaceuticals Announce Expansion of their Partnership for the Development of PV-267, Provid's Unique MS Drug Candidate
Date:11/17/2010

NEW YORK and NORTH BRUNSWICK, N.J., Nov. 17, 2010 /PRNewswire/ -- Provid Pharmaceuticals, Inc, a drug discovery company, and Fast Forward, LLC, the National Multiple Sclerosis Society's subsidiary devoted to bridging the gap between research and drug development, today announced an expansion of their partnership to support Provid's preclinical studies of their candidate MS drug, PV-267.  This novel, highly selective small molecule is designed to block a critical step in the autoimmune process of MS, which leads to the destruction of the body's protective myelin in the central nervous system and to the ultimate accumulation of disability.  

The expanded partnership will enable Provid to enhance knowledge of the immune mechanisms involved in the activity of PV-267, paving the way for future development and clinical studies.  The biological studies will be carried out by Dr. Thomas Forsthuber, Provid's collaborator and a leading immunologist at the University of Texas San Antonio.  

"The partnership between Fast Forward and Provid was begun in May 2009 and helped fund important research," noted Dr. Gary Olson, Provid's President and CEO.  "In these studies, PV-267 was shown to be active in an animal model of MS in transgenic mice that carry the human gene for HLA-DR2, a disease-associated molecule that is involved in the attack of the immune system on myelin, the insulating protein on nerves that are damaged in MS."  Dr. Olson added, "DR2 is present in about 60% of the MS population and PV-267 was designed to be a potent and selective blocker of DR2.  This specificity suggests that PV-267 could have a better safety profile compared with immune-modifying therapies since it will not affect other, normal immune responses."  

The partnership with Provid is one of a series of partnerships between Fast Forward and early stage biotechnology companies. "The results of our
'/>"/>

SOURCE Provid Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Fast Forward, Juvenile Diabetes Research Foundation and Axxam SpA Join Forces to Accelerate Development of Treatments for Multiple Sclerosis and Type 1 Diabetes
2. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
3. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
4. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
5. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
6. Raptor Pharmaceuticals Provides Update of Product Programs
7. Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay
8. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
9. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
10. Most Women With HIV and Their Health Care Providers Have Not Discussed How HIV Might Affect Them Differently Than Men
11. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... -- RnRMarketResearch.com adds Syringes and Needles ... provides an overview of syringes and needles currently ... databases, secondary and primary research. Complete ... spread across 124 pages, talking about 13 companies ... figures is now available at http://www.rnrmarketresearch.com/syringes-and-needles-pipeline-review-2015-market-report.html ...
(Date:7/31/2015)... Fla. , July 31, 2015  Xcelience, ... today that it has made a structured cash ... -based company specializing in milling, micronization and powder ... will help grow Powdersize,s business while simultaneously adding ... to Xcelience,s portfolio of capabilities. ...
(Date:7/31/2015)... and SAN DIEGO , July ... parent company Eisai Co., Ltd. (Headquarters: Tokyo ... "Eisai") and Halozyme Therapeutics, Inc. (Headquarters: San ... Helen Torley , "NASDAQ: HALO") have signed a clinical ... Halaven ® , "eribulin") in combination with Halozyme,s investigational ...
Breaking Medicine Technology:Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6
... Kosan Biosciences,Incorporated (Nasdaq: KOSN ) today ... alvespimycin, the company,s second-generation Hsp90 inhibitor, in,patients with ... to disrupt the activity of multiple oncogenes,and cell ... a,key signaling pathway in breast cancer. The objective ...
... study conducted in MDS - Vidaza therapy confers highly significant 9.4 ... to conventional care regimens, - Two year overall survival rate of 50.8% ... ... Pharmion Corporation,(Nasdaq: PHRM ) today announced the submission of a ...
Cached Medicine Technology:Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer 2Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer 3Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer 4Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 2Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 3Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 4Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 5Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 6Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 7
(Date:7/31/2015)... ... July 31, 2015 , ... ... been recognized in the 2015 Aster Awards national competition for a marketing communications ... Ocean City and surrounding communities in Coastal Maryland and Southern Delaware. , A ...
(Date:7/31/2015)... ... , ... BioViva USA, Inc. (“BioViva”), a to-clinic gene therapy company based in ... announces it has begun a fundraiser through Maximum Life Foundation (“MaxLife”) to use a ... MaxLife will grant 100% of the money raised to BioViva to help bring pioneering ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... 20-21, 2015 – Washington, DC, http://www.fdanews.com/importexportprogram , Having FDA-regulated products held ... have to. , Instead of risking containment — or even destruction — of ...
(Date:7/31/2015)... ... July 31, 2015 , ... Florida Hospital Tampa ... that was developed for targeted delivery of fluids to selected sites in the ... Florida Hospital Tampa with the device that provides direct, local delivery of chemotherapy ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Ticket Down is ... in Birmingham. The U.S. Women's National Soccer Team will face the Australia Women's National ... Thursday, September 17th at Ford Field in Detroit and the second match will occur ...
Breaking Medicine News(10 mins):Health News:Mullin/Ashley Associates Wins in the 2015 Aster Awards National Competition for Excellence in Medical Marketing 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 2Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 4Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4Health News:Cheap USA vs. Australia Tickets at Legion Field in Birmingham, AL: Ticket Down Slashes Ticket Prices for Australia vs. USWNT at Legion Field 2
... for years about the health risks of using the Chicago ... Chicago study, canoeing, kayaking, rowing, boating and fishing on the ... performing these same activities on other local waters -- a ... for swimmers at Lake Michigan beaches. The study is ...
... is providing a new route to get to and remove ... natural hole behind the molars, above the jawbone and beneath ... surgery, published in the October the Laryngoscope , the ... faster recovery and fewer complications than traditional approaches. And, because ...
... Oct. 25 (HealthDay News) -- ,Marijuana causes disruptions in ... people with schizophrenia, according to a new study. ... neurons in the brains of rats given a drug ... of marijuana. The effects of the drug on ...
... A new potential leukemia therapy targets only cancer cells, ... treatments affect cancer cells and healthy cells, causing significant ... and depression. This research is being presented at ... Meeting and Exposition in Washington, D.C., Oct. 23 ...
... TUESDAY, Oct. 25 (HealthDay News) -- Scientists have identified mutations ... have a potentially fatal blood clot after undergoing heart stent ... the drug Plavix (clopidogrel), a widely used blood thinner, and ... Oct. 26 issue of the Journal of the American ...
... Sox and Yankee fans alike sitting inches away from the television, ... away It might have been that very moment in 2003 when ... it might have been that very moment in 2004, when Boston,s Pokey ... devastation of 2003 began to fade from the memories of so many ...
Cached Medicine News:Health News:Boaters' risk of illness on Chicago River similar to other waterways 2Health News:Boaters' risk of illness on Chicago River similar to other waterways 3Health News:New 'scarless' surgery takes out tumors through natural skull opening 2Health News:Genes Could Highlight Plavix Users at Clot Risk After Stent 2Health News:A World Series to remember? 2
Shielding's Standard Coat Apron with open back allows for freedom of movement, maximum flexibility and increased comfort....
This set includes 2 small, 1 medium, 1 large gonad shields and a belt. The shields and belt is an interchangeable system attached by velcro....
Lap pad used to protect pelvic regions...
This apron was designed by Pulse Medical-RCI for optimal protection. Your comfort is also a primary concern so a wide support belt and shoulder pads are standard. When properly fitted, an overlapping...
Medicine Products: